Progress in the discovery and development of antisense therapeutics continues at a rapid pace. Detailed understanding of the pharmacokinetic, toxicological and pharmacological properties of phosphorothioate oligonucleotides is now available. Further, an ever-increasing body of information is available about new and improved chemical classes of antisense drugs that are progressing toward clinical trials.